On June 7th, Gelunhui reported that Yantai Zhenghai Bio-Tech (stock code: 300653.SZ) stated on its investor interaction platform that the company's active biological bone products are mainly used to fill bone defects caused by trauma or surgery that do not affect bone structure stability. During the use of active biological bone, doctors determine the choice of internal fixators according to clinical needs. The company currently does not provide related supporting medical devices. Human umbilical cord mesenchymal stem cells are currently in the product process validation stage. The company will continue to focus on the field of regenerative medicine, actively research and develop products and technologies including signal molecules, seed cells, additive manufacturing, genetic engineering, and synthetic biology, to create a multi-disciplinary and comprehensive tissue regeneration R&D platform for brackets, indicators, cells, and other materials, thus realizing the expansion of the layout in the field of regenerative medicine.